The best indicator for Biogen (BIIB)
We backtested 366 indicators across daily, weekly and hourly charts on real Biogen (BIIB) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
Connors RSI
On the daily chart, this is the strongest risk-adjusted edge we found for Biogen (BIIB) over ~34.7 years — beating buy-and-hold by 7.5% CAGR.
Best multi-indicator combo
Going long only when all 2 agree was the strongest confluence setup we found for Biogen (BIIB) — trailing buy-and-hold by 7.7% CAGR, out-of-sample. Fewer, higher-conviction trades than any single indicator.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | Connors RSI ✓ | Daily | 20.2% | 0.72 | -50.0% | 64.2% | 405 | 7.5% |
| 2 | Fibonacci Pivots | Daily | 18.7% | 0.66 | -68.4% | 52.1% | 1419 | 6.0% |
| 3 | Connors RSI-2 ✓ | Daily | 16.1% | 0.63 | -44.8% | 59.4% | 389 | 3.4% |
| 4 | Pivot Points (Standard) | Daily | 14.4% | 0.57 | -71.4% | 52.2% | 1273 | 1.7% |
| 5 | TEMA 20/50 Cross ✓ | Weekly | 14.8% | 0.56 | -69.5% | 51.5% | 33 | 2.2% |
| 6 | MA Envelope ✓ | Daily | 14.3% | 0.54 | -62.9% | 62.8% | 290 | 1.6% |
| 7 | McGinley 200 Trend ✓ | Daily | 15.9% | 0.54 | -76.2% | 23.5% | 17 | 3.2% |
| 8 | T3 8/21 Cross ✓ | Weekly | 14.6% | 0.54 | -68.7% | 52.9% | 34 | 2.0% |
| 9 | Projection Bands ✓ | Daily | 12.8% | 0.51 | -56.4% | 60.8% | 306 | 0.2% |
| 10 | QQE ✓ | Weekly | 14.3% | 0.51 | -80.4% | 43.1% | 102 | 1.6% |
| 11 | Murrey Math Lines ✓ | Daily | 12.5% | 0.5 | -63.5% | 74.7% | 95 | -0.1% |
| 12 | McGinley 100 Trend ✓ | Daily | 13.0% | 0.49 | -85.4% | 25.8% | 31 | 0.3% |
| 13 | DEMA 20/50 Cross ✓ | Weekly | 12.1% | 0.49 | -75.2% | 40.7% | 27 | -0.6% |
| 14 | EMA 13/48 Cross | Weekly | 12.4% | 0.49 | -80.1% | 36.8% | 19 | -0.3% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Biogen (BIIB), Connors RSI on the daily timeframe gave the best balance of return and risk in our test. It beat buy-and-hold — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.